Mitsubishi UFJ Asset Management Co. Ltd. Increases Position in CureVac (NASDAQ:CVAC)

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of CureVac (NASDAQ:CVAC) by 45.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,122 shares of the company’s stock after purchasing an additional 13,687 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in CureVac were worth $184,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Deutsche Bank AG lifted its holdings in CureVac by 5.1% during the 3rd quarter. Deutsche Bank AG now owns 72,510 shares of the company’s stock worth $495,000 after buying an additional 3,491 shares during the last quarter. Swiss National Bank lifted its stake in CureVac by 1.8% during the third quarter. Swiss National Bank now owns 221,406 shares of the company’s stock worth $1,462,000 after purchasing an additional 3,925 shares during the last quarter. Optiver Holding B.V. boosted its holdings in CureVac by 2,407.0% in the third quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock valued at $47,000 after purchasing an additional 6,571 shares in the last quarter. Federated Hermes Inc. raised its holdings in CureVac by 33.3% during the third quarter. Federated Hermes Inc. now owns 40,000 shares of the company’s stock worth $273,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Vontobel Holding Ltd. purchased a new stake in shares of CureVac during the 4th quarter worth approximately $45,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CVAC shares. Guggenheim reiterated a “neutral” rating on shares of CureVac in a research note on Friday, April 5th. Leerink Partnrs cut CureVac from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 25th. Finally, SVB Leerink lowered CureVac from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $12.00 to $4.00 in a research report on Thursday, April 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, CureVac presently has an average rating of “Hold” and a consensus price target of $8.33.

CureVac Trading Up 1.5 %

NASDAQ CVAC opened at $3.97 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.43 and a current ratio of 2.57. CureVac has a one year low of $2.21 and a one year high of $12.36. The firm’s fifty day moving average is $2.95 and its two-hundred day moving average is $3.82. The firm has a market cap of $888.80 million, a PE ratio of -3.10 and a beta of 2.51.

CureVac (NASDAQ:CVAC) last announced its quarterly earnings data on Wednesday, April 24th. The company reported ($0.42) earnings per share (EPS) for the quarter. CureVac had a negative net margin of 483.81% and a negative return on equity of 41.85%. The firm had revenue of $24.30 million during the quarter. Analysts expect that CureVac will post -0.82 earnings per share for the current year.

CureVac Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.